



FORM PTO-1449			DOCKET NO.: 58614 (71432)		SERIAL NO.: 10/776,933		
INFORMATION DISCLOSURE STATEMENT			APPLICANT(S): B. Hansen et al.				
			FILING DATE: February 10, 2004		GROUP NO.: Unknown		
FOREIGN PATENT DOCUMENTS							
		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES/NO
DS	AA	WO 03/006475 A3	01/23/03	WIPO			
	AB	WO 02/28875 A2	04/11/02	WIPO			
	AC	WO 02/094250 A2	11/28/02	WIPO			
	AD	WO 00/66604	11/09/00	WIPO			
	AE	WO 00/56748	09/28/00	WIPO			
	AF	WO 00/56746	09/28/00	WIPO			
	AG	WO 00/12524	03/09/00	WIPO			
	AH	WO 99/38963	08/05/99	WIPO			
DS	AI	WO 99/14226	03/25/99	WIPO			
OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.)							
DS	AJ	Yokomizo et al., <i>Cancer Res.</i> 55:4293-4296 (1995).					
	AK	Kahlos et al., <i>Int. J. Cancer</i> 20:95:198-204 (2001).					
	AL	Holmgren., <i>J. Biol. Chem.</i> 264(24):13963-13966 (1989).					
	AM	Holmgren, <i>Ann. Rev. Biochem.</i> 54:237-271 (1985).					
	AN	Powis, et al., <i>Annu. Rev. Biophys. Biomol. Struct.</i> 30:421-455 (2001).					
	AO	Gasdaska et al., <i>Biochim. Biophys. Acta</i> 1218:292-296 (1994).					
	AP	Matthews, et al., <i>Nucleic Acids Res.</i> 20(15):3821-3830 (1992).					
	AQ	Cromlish et al., <i>J. Biol. Chem.</i> 264(30):18100-18109 (1989).					
	AR	Bannister et al., <i>Oncogene</i> 6:1243-1250 (1991).					
	AS	Ueno, et al., <i>J. Biol. Chem.</i> 274(50):35809-35815 (1999).					
	AT	Grippo, et al., <i>J. Biol. Chem.</i> 258(22):13658-13664 (1983).					
	AU	Abate et al., <i>Science</i> 249:1157-1161 (1990).					
	AV	Welsh et al., <i>Cancer Res.</i> 62:5089-5095 (2002).					
	AW	Gasdaska et al., <i>Cell Growth Differ.</i> 6:1643-1650 (1995).					
	AX	Schenk et al., <i>J. Immunol.</i> 156:765-771 (1996).					
	AY	Taniguchi et al., <i>Nucleic Acids Res.</i> 24(14):2746-2752 (1996).					
	AZ	Rubartelli et al., <i>J. Biol. Chem.</i> 267(34):24161-24164 (1992).					
	BA	Nakamura et al., <i>Cancer</i> 69(8):2091-2097 (1992).					
	BB	Baker et al., <i>Cancer Res.</i> 57:5162-5167 (1997).					
	BC	Oblong et al., <i>J. Biol. Chem.</i> 269(16):11714-11720 (1994).					
	BD	Grogan et al., <i>Hum. Pathol.</i> 31(4):475-481 (2000).					
	BE	Soini, et al. <i>Clin. Cancer Res.</i> 7:1750-1757 (2001).					
	BF	Fujii et al., <i>Cancer</i> 68:1583-1591 (1991).					
	BG	Nakamura et al., <i>Cancer Detect. Prev.</i> 24(1):53-60 (2000).					
DS	BH	Hariharan et al., <i>Elsevier Science B.V.</i> 173: 265-270 (1996).					
Examiner: /Dana Shin/					Date: 10/16/2006		



PTO/SB/08a/b (08-03)

Approved for use through 07/31/2006. OMB 0851-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Project of 1995, persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Application Number	10/776,933-Conf. #2102
				Filing Date	February 10, 2004
				First Named Inventor	Bo Hansen
				Art Unit	N/A
				Examiner Name	Not Yet Assigned
Sheet	1	of	2	Attorney Docket Number	58614(1432)

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number Number-Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
DS	BA	WO-01/48190-A2	07-05-2001	Exiqon A/S		

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.		T ²
DS	CA	E.A.L. Biessen et al.: "Design of a targeted peptide nucleic acid prodrug to inhibit hepatic human microsomal triglyceride transfer protein expression in hepatocytes" Bioconjugate Chemistry, Vol. 13, 2002, pages 295-302, XP002290397		
DS	CB	K. Hori et al.: "Expression of Adult T Cell Leukemia-derived Factor / Human Thioredoxin in Human Gliomas" Mie Medical Journal, Vol. 44, No. 1, 1994, pages 19-24, XP008033406		
DS	CC	T. Andoh et al.: "The Roles of Thioredoxin in Protection against Oxidative Stress-induced Apoptosis in SH-SY5Y Cells" The Journal of Biological Chemistry, Vol. 277, No. 12, 2002, pages 9655-9660, XP002290398		
DS	CD	M. Saitoh et al.: "Mammalian thioredoxin is a direct inhibitor of apoptosis signal-regulating kinase (ASK) 1" EMBO Journal, Vol. 17, No. 9, 1998, pages 2596-2606, XP002106020		
DS	CE	J. Kurreck et al.: "Design of antisense oligonucleotides stabilized by locked nucleic acids" Nucleic Acids Research, Vol. 30, No. 9, 2002, pages 1911-1918, XP002281375		
DS	CF	K. Morita et al.: "2'-O, 4'-C-Ethylene-Bridged Nucleic Acids (ENA): Highly Nuclease-Resistant and Thermodynamically Stable Oligonucleotides for Antisense Drug" Bioorganic and Medicinal Chemistry Letters, Vol. 12, 2002, pages 73-76, XP002290399		
DS	CG	D.A. Braasch et al.: "Antisense inhibition of gene expression in cells by oligonucleotides incorporating locked nucleic acids: effect of mRNA target sequence and chimera design" Nucleic Acids Research, Vol. 30, No. 23, 2002, pages 5160-5167, XP002290400		
DS	CH	K. H. Altman et al.: "Novel Chemistry" 1998, Applied Antisense Oligonucleotide Technology, Wiley-Liss, Inc., U.S., Chapter 4, pages 73-107, XP002119324		
DS	CI	D.A. Braasch et al.: "Locked nucleic acid (LNA): fine-tuning the recognition of DNA and RNA" Chemistry and Biology, Vol. 8, No. 1, 2001, pages 1-7, XP002255827		
DS	CJ	H. Ørum et al.: "Locked nucleic acids: A promising molecular family for gene-function analysis and antisense drug development" Current Opinion in Molecular Therapeutics, Vol. 3, No. 3, 2001, pages 239-243, XP 001179829		
DS	CK	K. Fluiter et al.: "In vivo tumor growth inhibition and biodistribution studies of locked nucleic acid (LNA) antisense oligonucleotides" Nucleic Acids Research, Vol. 31, No. 3, 2003, pages 953-962, XP002290401		

Examiner Signature	/Dana Shin/	Date Considered	10/16/2006
--------------------	-------------	-----------------	------------

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.


Substitute for form 1449A/B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Complete If Known	
				Application Number	10/776,933-Conf. #2102
				Filing Date	February 10, 2004
				First Named Inventor	Bo Hansen
				Art Unit	N/A
				Examiner Name	Not Yet Assigned
Sheet	2	of	2	Attorney Docket Number	58614(1432)

DS	CL	A.S. Rait et al.: "Inhibitory effects of the combination of HER-2 antisense oligonucleotide and chemotherapeutic agents used for the treatment of human breast cancer" Cancer Gene Therapy, Vol. 8, No. 10, 2001, pages 728-739, XP0088005112	
----	----	---	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature	/Dana Shin/	Date Considered	10/16/2006
--------------------	-------------	-----------------	------------



PTO/SB/08a/b (08-03)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PJO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Complete If Known	
				Application Number	10/776,933-Conf. #2102
				Filing Date	February 10, 2004
				First Named Inventor	Bo Hansen
				Art Unit	N/A
				Examiner Name	Not Yet Assigned
Sheet	1	of	1	Attorney Docket Number	58614(71432)

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number Number-Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear

FOREIGN PATENT DOCUMENTS							
Examiner Initials*	Cite No. ¹	Foreign Patent Document		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ³
		Country Code ⁴	Number-Kind Code ⁵ (if known)				

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
DS	CA	A. Chin, "On the Preparation and Utilization of Isolated and Purified Oligonucleotides", Public Collection of the Kathrine R. Everett Law Library of the University of North Carolina, March 2002 (On CD)	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ** CITE NO.: Those document(s) which are marked with an double asterisk (**) next to the Cite No. are not supplied because they were previously cited by or submitted to the Office in a prior application relied upon in this application for an earlier filing date under 35 U.S.C. 120.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature	/Dana Shin/	Date Considered	10/16/2006
--------------------	-------------	-----------------	------------



PTO/SB/08a/b (08-03)

Approved for use through 07/31/2008. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Complete if Known	
				Application Number	10/776,933
				Filing Date	February 10, 2004
				First Named Inventor	Bo Hansen
				Art Unit	1635
				Examiner Name	J. Ashen
Sheet	1	of	1	Attorney Docket Number	58614(71432)

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)			
DS	AA	2004-0248840 A1	12/9/04		
DS	AB	2005-0014712 A1	1/20/05		

FOREIGN PATENT DOCUMENTS							
Examiner Initials*	Cite No. ¹	Foreign Patent Document		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)					

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ** CITE NO.: Those document(s) which are marked with an double asterisk (**) next to the Cite No. are not supplied because they were previously cited by or submitted to the Office in a prior application relied upon in this application for an earlier filing date under 35 U.S.C. 120.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature	/Dana Shin/	Date Considered	10/16/2006
-----------------------	-------------	--------------------	------------